ArticleScientific reports2025
Circulating biomarkers in patients with progressive fibrosing interstitial lung disease treated with nintedanib: a pilot study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association ofInternational journal of molecular sciences · 2026Article
- Progressive pulmonary fibrosis: the importance of identification and intervention.European respiratory review : an official journal of the European Respiratory Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive fibrosing interstitial lung diseases (PF-ILDs) are characterized by persistent progression and have limited treatment options. The identification of reliable biomarkers to monitor fibrosis and therapeutic response remains a clinical challenge. This study investigated circulating plasma biomarkers associated with PF-ILDs and their potential role in monitoring disease evolution during nintedanib treatment. From 127 putative fibrosis biomarkers, seven candidates were identified with high diagnostic value (area under the curve [AUC] > 0.7), of which five (IGFBP2, PTX3, LGALS1, LGALS9, and MMP2) showed significant dynamic changes (assessed by longitudinal plasma proteomic analysis) in PF-ILD patients treated with 12-months nintedanib, correlating with improvements in forced vital capacity and diffusing capacity of the lung for carbon monoxide. Principal component analysis identified a shift in molecular profiles over time, suggesting nintedanib-induced modulation of these biomarkers. Receiver operating characteristic analysis demonstrated that while LGALS9 maintained a stable predictive value during nintedanib treatment, LGALS1, IGFBP2, PTX3, and MMP2 exhibited increasing AUC scores, indicating their potential role in monitoring fibrosis progression. We also identified optimal biomarker cut-off values at 12 months, which may provide reliable thresholds for fibrosis assessment. In conclusion, our exploratory analysis identified five biomarkers whose plasma concentrations changed during antifibrotic treatment, highlighting their potential prognostic value. Further validation in larger cohorts is needed to confirm their clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.